Abstract Human cytomegalovirus (HCMV) retinitis is a serious sight threatening disease affecting immunocompromised individuals such as acquired immuno
deficiency syndrome patients with CD4 cell counts less than 50 cells/μl. Ganciclovir was the first anti-HCMV drug approved by Food and Drug Administration for disease management. Owing to its virustatic properties, indefinite maintenance of ganciclovir levels in retina is necessary to prevent disease progression. Previously, management of retinitis with ganciclovir was two fold with induction and
maintenance therapy via daily infusions. Systemic toxicity with such infusions prompted the development of local
ganciclovir therapy by direct…
